Literature DB >> 18314560

Endogenous melatonin levels and the fate of exogenous melatonin: age effects.

I V Zhdanova1, R J Wurtman, A Balcioglu, A I Kartashov, H J Lynch.   

Abstract

This study examines the range of serum melatonin concentrations that occur among young and older adults, and tests the effects of orally administered melatonin on the serum and saliva concentrations of the hormone. Healthy volunteers (20-36 per study), aged 20-73 years, were divided into two groups on the basis of age (29.2 +/- 6.5 and 60 +/- 8.8 years). For study 1: Serum melatonin levels were measured at 15 to 60 min intervals over a 25 h period using a radioimmunoassay. For study 2: serum and saliva melatonin levels were measured before and at intervals after the administration of a 0.3 mg dose of melatonin at 11.00 h. The younger subjects had significantly higher peak endogenous melatonin concentrations (+/- SD) and greater inter-individual variability (100.9 +/- 48.6 pg/ml) than the older subjects (34.5 +/- 15.4 pg/ml). Mean melatonin levels following treatment with the hormone tended to be higher and were significantly more variable among the group of older volunteers (254.5 +/- 145.7) than among the younger group (170.2 +/- 22.0 pg/ml). We conclude that although the peak endogenous serum melatonin levels are lower in elderly adults, the increment in serum melatonin levels induced by a low oral dose of the hormone is greater and more variable among people over 48 years old.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 18314560     DOI: 10.1093/gerona/53a.4.b293

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  22 in total

1.  EEG sleep spectra in older adults across all circadian phases during NREM sleep.

Authors:  Mirjam Münch; Edward J Silva; Joseph M Ronda; Charles A Czeisler; Jeanne F Duffy
Journal:  Sleep       Date:  2010-03       Impact factor: 5.849

Review 2.  Clinical pharmacokinetics of melatonin: a systematic review.

Authors:  Nathja Groth Harpsøe; Lars Peter Holst Andersen; Ismail Gögenur; Jacob Rosenberg
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

3.  Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults.

Authors:  Nalaka S Gooneratne; Alena Y Z Edwards; Chen Zhou; Norma Cuellar; Michael A Grandner; Jeffrey S Barrett
Journal:  J Pineal Res       Date:  2012-02-21       Impact factor: 13.007

Review 4.  The Safety of Melatonin in Humans.

Authors:  Lars Peter Holst Andersen; Ismail Gögenur; Jacob Rosenberg; Russel J Reiter
Journal:  Clin Drug Investig       Date:  2016-03       Impact factor: 2.859

5.  Chronic Melatonin Treatment Prevents Memory Impairment Induced by Chronic Sleep Deprivation.

Authors:  Karem H Alzoubi; Fadia A Mayyas; Omar F Khabour; Fatima M Bani Salama; Farah H Alhashimi; Nizar M Mhaidat
Journal:  Mol Neurobiol       Date:  2015-06-18       Impact factor: 5.590

Review 6.  Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature.

Authors:  Esmée M S Vural; Barbara C van Munster; Sophia E de Rooij
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

7.  Scheduled bright light for treatment of insomnia in older adults.

Authors:  Leah Friedman; Jamie M Zeitzer; Clete Kushida; Irina Zhdanova; Art Noda; Tina Lee; Bret Schneider; Christian Guilleminault; Javaid Sheikh; Jerome A Yesavage
Journal:  J Am Geriatr Soc       Date:  2009-01-29       Impact factor: 5.562

Review 8.  Melatonin and the skeleton.

Authors:  A K Amstrup; T Sikjaer; L Mosekilde; L Rejnmark
Journal:  Osteoporos Int       Date:  2013-05-29       Impact factor: 4.507

9.  Night-time exogenous melatonin administration may be a beneficial treatment for sleeping disorders in beta blocker patients.

Authors:  Auda Fares
Journal:  J Cardiovasc Dis Res       Date:  2011-07

Review 10.  Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders.

Authors:  Lindsay M Melhuish Beaupre; Gregory M Brown; Vanessa F Gonçalves; James L Kennedy
Journal:  Transl Psychiatry       Date:  2021-06-02       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.